Table 1. Patient characteristics.
| No | 200 |
| Age median (year) (range) | 73 (52–92) |
| ECOG PS | |
| 0 | 42 (21.0% |
| 1 | 91 (45.5%) |
| 2–3 | 67 (33.5%) |
| Gleason score at diagnosis (196 patients) | |
| <8 | 95 (48.5%) |
| ⩾8 | 101 (51.5%) |
| Previous endocrine therapies | |
| LHRH-A | 182 (91.0%) |
| LHRH-A+antiandrogens | 18 (9.0%) |
| PSA (ng ml−1) (198 patients)a | 118.0 (0.1–9000.0) |
| Alkaline phosphatase (U l−1) (186 patients)a | 165.0 (47.0–6000.0) |
| NTx (nmol mmol−1 creatinine) (103 patients)a | 96.0 (11.6–662.0) |
| Ca (mmol l−1) (184 patients)a | 2.35 (1.91–4.20) |
| Hb (g dl−1) (182 patients)a | 12.1 (7.3–15.6) |
| Albumin (g dl−1) (170 patients)a | 3.6 (1.9–6.7) |
| LDH (U l−1) (178 patients)a | 405 (136–3011) |
| Androgen deprivation duration (months) (188 patients)a | 24.5 (2.03–228.0) |
| Disease extent in bone (number of sites) (198 patients)a | 6 (1–9 or more) |
| Pain score (200 patients)a | 5 (0–16) |
| Types of bone lesions (190 patients) | |
| Lytic | 14 (7.4%) |
| Mixed | 42 (22.1%) |
| Blastic | 134 (70.5%) |
a
Data are median (range).